Filtering by:
Lung CancerFDA Approves Opdivo (Nivolumab) for Small Cell Lung Cancer
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).
Lung Cancer Rates in Young Women Now Higher Than in Young Men
Researchers from the American Cancer Society and the National Cancer Institute have found rates of lung cancer are higher in women than men among white and Hispanic people born since 1965.
Annual Report to the Nation: Cancer Death Rates Continue Long Decline
The death rate from cancer in the United States is continuing to fall among men, women, and children, according to the latest Annual Report to the Nation on the Status of Cancer.
Researchers Report Advances in Lung Cancer Immunotherapy
Scientists presenting at the American Association for Cancer Research Annual Meeting in Chicago have found new and promising ways to use immunotherapy to treat people with some types of non-small cell lung cancer (NSCLC).
12 Key Findings from the New Edition of The Tobacco Atlas
Learn about the physical, social, and economic harms of tobacco and about evidence-based solutions to advance toward a tobacco-free world.
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
Lung Cancer Dream Team Makes Progress
Dr. Pasi Janne gives an update on the research lead by the Lung Cancer Dream Team, which was created and funded by a partnership between Stand Up For Cancer and The American Cancer Society.